The revival of trials seems to vindicate the stance of the ICMR, which recently reported that HCQ had helped patients in India, although some doctors have alleged that it only works as a placebo To use or not to?
It’s a question people have of hydroxychloroquine (HCQ), an anti-malarial pill, touted as an anti-covid drug. The dilemma has also confronted the World Health Organization, which is reported to have resumed trials, citing the all-clear of a safety review, after having suspended them.
A research paper in the venerable Lancet had raised concerns that HCQ could cause cardiac problems and raise mortality risks.